Clinical Trials Logo

Hematological Malignancies clinical trials

View clinical trials related to Hematological Malignancies.

Filter by:

NCT ID: NCT00500578 Completed - Clinical trials for Hematological Malignancies

Intermittent Use of Aerosolized Ribavirin for Treatment of RSV

Start date: February 2003
Phase: Phase 4
Study type: Interventional

Primary Objectives: 1. To determine whether aerosolized ribavirin is effective when given at an intermittent dose over 3 hours every 8 hours for therapy of RSV upper respiratory tract infection (URI) and whether it can prevent progression to pneumonia. 2. To determine the effect of this regimen on persistence of viral shedding.

NCT ID: NCT00438178 Completed - Clinical trials for Hematological Malignancies

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies

Start date: October 2005
Phase: Phase 1
Study type: Interventional

Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogneic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells.

NCT ID: NCT00423124 Completed - Clinical trials for Hematological Malignancies

Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies

Start date: July 2002
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of the study is to obtain immune reconsitutuion as well as reduction of infective episodes and disease relapse in patient with haematological malignancies who underwent SCT(and subsequent T lymphocytes infusions) and selectively controlling GvHD.

NCT ID: NCT00382759 Completed - Clinical trials for Hematological Malignancies

Nonmyeloablative Stem Cell Transplant in Elderly

Start date: March 2000
Phase: Phase 2/Phase 3
Study type: Interventional

The study aimed to evaluate the efficacy of a nonmyeloablative conditioning consisting of fludarabine and total body irradiation in patients older than 60 years of age

NCT ID: NCT00379587 Completed - Clinical trials for Hematological Malignancies

Rituximab for Prevention of Chronic GVHD

Start date: September 2006
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to determine if administration of rituximab after allogeneic stem cell transplantation can reduce the incidence of chronic GVHD. Chronic GVHD is a medical condition that can occur after bone marrow or stem cells are transplanted form one individual to another. After the transplant, the donor immune system may recognize the recipient body as foreign and may attempt to "reject" the body. Rituximab is a drug that interferes with the immune system function by specifically targeting B cells and killing them.

NCT ID: NCT00348959 Completed - Clinical trials for Hematological Malignancies

An Evaluation of the Effect of 'Open Window' on Psychological Well-being and Experience of Stem Cell Transplantation

Start date: August 2006
Phase: N/A
Study type: Interventional

The 'Open Window' Study is a prospective longitudinal study using a 4 group randomised control trial design to evaluate the psychological effect of 'Open Window' on the consequences of long term isolation on patients undergoing stem cell transplantation treatment of haematological malignancies. This study uses a randomised control trial design, which is widely used in healthcare settings to test the effects of interventions and testing cause and effect relationships between variables. A mixed methods approach for data collection and data analysis is being used. This will facilitate measurement of patients' psychological response to 'Open Window' using questionnaires and exploration of subjective feelings in relation to personal experiences of having a stem cell transplant through semi structured interviews. Hypothesis to be tested 'Open Window' has no effect on patients' levels of anxiety, depression, or distress when undergoing a stem cell transplant. Results: Of the 199 patients in the study, 96 were randomized to the intervention group and 103 to the control group. Participants in the intervention group had significantly reduced levels of anxiety on the day before transplant (P = 0.001), at day 7 (P = 0.041), and day 60 (P = 0.035). There was a significant reduction in depression before transplant (P= 0.022). Participants in the intervention group reported better experiences (P < 0.005).

NCT ID: NCT00179764 Completed - Malignant Melanoma Clinical Trials

Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])

Start date: March 10, 2000
Phase: N/A
Study type: Interventional

The purpose of this research study is to evaluate the effectiveness of transplantation of high doses of peripheral blood stem cells (stem cells are special cells found in the blood and bone marrow that produce new blood cells) after treatment with non-myeloablative chemotherapy (not toxic to the bone marrow). In addition, this study will assess the side effects of the transplant.

NCT ID: NCT00163644 Active, not recruiting - Clinical trials for Hematological Malignancies

RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT

Start date: November 2003
Phase: N/A
Study type: Interventional

The hypothesis is that exercise will improve the physical performance and quality of life of bone marrow/ haemopoietic stem cell transplants.The aim of the trial is to provide definite clinical evidence as to which( if any) type of exercise is most beneficial for this patient population. It is also aimed at improving the provision of physiotherapy services to this group of patients.

NCT ID: NCT00129155 Recruiting - Clinical trials for Hematological Malignancies

MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies

Start date: February 2005
Phase: Phase 2
Study type: Interventional

In this study, treosulfan is evaluated for conditioning in allogenic stem cell transplantation. The procedure and the follow-up are the same as in standard allogenic transplant. The donor is unrelated (identical HLA). The graft is haematological peripheral blood stem cell. The conditioning with reduced intensity is: fludarabine (from day -6 to day -2), treosulfan (from day -6 to day -4) and thymoglobuline (from day -2 to day -1).

NCT ID: NCT00088101 Completed - Lymphoma Clinical Trials

STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors

Start date: February 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, toxicity and patient tolerance of STA-5312 administered intravenously to patients with relapsed or refractory hematological malignancies and patients with solid tumors.